PRMT
Covalent modifications of histone tails have fundamental roles in chromatin structure and function. One such modification, lysine methylation, has important functions in many biological processes that include heterochromatin formation, X-chromosome inactivation and transcriptional regulation. The DNA within our cells exists in the form of chromatin. The basic building block of chromatin is the nucleosome, a structure consisting of an octamer of four core histone proteins around which 147 base pairs of DNA is wrapped. Core histones are subject to a large number of covalent modifications (PTMs: Post Translational Modifications) including acetylation, methylation, phosphorylation and ubiquitination. Histone methylation occurs on arginine and lysine residues and is catalyzed by enzymes belonging to three distinct families of proteins: the protein arginine specific methyl transferase (PRMT1) family, the SET-domain-containing protein family, and the non-SET-domain proteins DOT1/DOT1L. Unlike acetylation, which generally correlates with transcriptional activation, histone lysine methylation can signal either activation or repression, depending on the sites of methylation. Similar to the discovery that bromodomains can recognize acetylated lysines, studies on histone methylation identified at least three protein motifs (the Chromo-, the Tudor-, and the WD40-repeat domain) that are capable of forming specific interactions with methylated lysine residues of histone[1],[2].
Histone methyltransferases listed: HMTase, PRMT
[1] C. Martin, Y. Zhang. The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 2005, 6, 838-849.
[2] E.L. Greer, Y. Shi . Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genetics 2012, 13, 343-357
Axon ID | Name | Description | From price | |
---|---|---|---|---|
2863 | AMI-1 | Inhibitor of PRMT | €99.00 | |
2210 | C 7280948 | Sulfone inhibitor of PRMT1 | €85.00 | |
2709 | CMP5 | Inhibitor of PRMT5 | €95.00 | |
2831 | EPZ 015666 | Potent, selective and orally available inhibitor of PRMT5 | €125.00 | |
3750 | GSK3326595 | Orally active, potent, selective, SAM uncompetitive, peptide competitive, slow binding inhibitor of protein arginine methyltransferase 5 (PRMT5) | Inquire | |
3919 | GSK3368715 hydrochloride | A first-in-class, orally active, potent and selective, SAM-Noncompetive inhibitor of Type I Protein Arginine Methyltransferases (PRMTs) | Inquire | |
2710 | HLCL65 hydrochloride | Inhibitor of PRMT5 | €105.00 | |
3754 | JNJ-64619178 dihydrochloride | SAM-pocket binding (SAM Competitive) PRMT5 inhibitor | Inquire | |
3796 | MRTX1719 hydrochloride | Inhibitor of the PRMT5.MTA complex | Inquire | |
3681 | MS023 dihydrochloride | Potent, cell-active, and Type I selective PRMT inhibitor | €90.00 | |
3798 | PF-06855800 | SAM-pocket-binding (SAM competitive) PRMT5 inhibitor | Inquire | |
3692 | PF-06939999 dihydrochloride | SAM competitive PRMT5 inhibitor | Inquire | |
2211 | PRMT3 inhibitor 1 | Allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) | €105.00 | |
2625 | SGC2085 | Potent and selective CARM1 inhibitor (aka PRMT4) | €120.00 | |
2945 | SGC707 | First-in-class, potent, selective and cell-active allosteric inhibitor of PRMT3 | €90.00 |